Key Considerations Related to Medical Device, Pharmaceutical, and Biotech Arrangements

• February 14, 2025

With the increased scrutiny on kickbacks regarding medical device, pharmaceutical, and biotech arrangements, there has been an uptick in enforcement activity specific to the use of physicians, advanced practice providers, and other health care providers who consult, speak, serve as advisory board members, or otherwise lend their expertise. Tynan Kugler, Principal, PYA, Mara Smith Kouba, Counsel, Bristol Myers Squibb, and Jonathan Porter, Partner, Husch Blackwell LLP, discuss key regulatory and compliance considerations associated with recent medical device, pharmaceutical, and other biotech settlements (including the Janssen case) and how life sciences companies can navigate the current enforcement environment while engaging physicians and other providers.